Cost-utility Analysis of PD-1/PD-L1 Inhibitor Combination Therapies as First-line Treatment for Advanced Non-small-cell Lung Cancer
10.13748/j.cnki.issn1007-7693.20232793
- VernacularTitle:PD-1/PD-L1抑制剂联合疗法一线治疗晚期非小细胞肺癌的成本-效用分析
- Author:
HE Yimin
1
;
NIAN Zilin
1
;
LIU Wenbin
2
;
YANG Lin
2
;
DONG Liangliang
2
;
ZHAO Qiuling
2
Author Information
1. School of Pharmacy, Fujian Medical University, Fuzhou 350004, ChinaClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China
2. Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China
- Publication Type:Journal Article
- Keywords:
non-small-cell lung cancer;
immune-checkpoint inhibitors;
Markov model;
cost-utility analysis;
pharmacoeconomics
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(13):1820-1829
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE
To compare the cost-utility of eight programmed death 1(PD-1)/programmed cell death-ligand 1(PD-L1) inhibitor combination regimens for first-line treatment of advanced non-small cell lung cancer(NSCLC) from the perspective of Chinese healthcare system.
METHODS
Relevant data were derived from a published network meta-analysis and randomized controlled trails, a three-state Markov model was established to analyze the cost-utility of eight immunotherapy combinations. The robustness of results were validated through sensitivity analyses and a series of scenario analyses was also conducted.
RESULTS
The incremental cost-utility ratio(ICUR) of the sintilizumab plus chemotherapy group and the tislelizumab plus chemotherapy group were ￥125143.88/quality adjusted life year(QALY) and ￥189609.64/QALY, respectively, which were less than the willingness-to-pay(WTP) threshold of ￥257094/QALY, and all the ICURs of other PD-1/PD-L1 inhibitor combination regimens exceeded the WTP threshold and were not economical. Scenario analyses found that even if the medical insurance reimbursement ratio reached 80%, the different combinations of pembrolizumab, nivolumab and atezolizumab were not economical.
CONCLUSION
Compared with other PD-1/PD-L1 inhibitor combination regimens, sintilizumab plus chemotherapy and tislelizumab plus chemotherapy have cost-utility advantages in the first-line treatment of advanced NSCLC, which can provide a certain reference for selecting a reasonable treatment plan for NSCLC patients.
